Maintenance therapy aims to sustain a state of ongoing disease remission. This article discusses the results of randomized trials that suggest that specific subgroups of patients with follicular lymphoma should receive maintenance therapy with rituximab.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Steward, W. P. et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61, 441–447 (1988).
Rohatiner, A. Z. S. et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. Oncol. 23, 2215–2223 (2005).
Ezdinli, E. Z. et al. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 60, 156–160 (1987).
Ghielmini, M. et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 103, 4416–4423 (2004).
Hainsworth, J. D. et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088–1095 (2005).
Hochster, H. et al. Maintenance rituximab after cyclophosphamide, vincristine and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607–1614 (2009).
van Oers, M. H. J. et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108, 3295–3301 (2006).
Forstpointner, R. et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003–4008 (2006).
Vidal, L. et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101, 248–255 (2009).
Gajraj, E., Chung, H., Longson, C. & Stevens, A. Rituximab for follicular non-Hodgkin lymphoma. Lancet Oncol. 9, 320–321 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. F. Seymour is a Consultant, on the Speakers Bureau and receives grant/research support from Roche.
Rights and permissions
About this article
Cite this article
Seymour, J. Follicular lymphoma: maintenance therapy is (often) indicated. Nat Rev Clin Oncol 6, 624–626 (2009). https://doi.org/10.1038/nrclinonc.2009.159
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.159
